GNLX

Conviction 59HealthcareScan · Thu, Jun 25, 2026

GNLX$2.91+1.93%

ResistanceSupportVol 14Insider sell

Vol MA14 223.63K

Mar 26Apr 14May 1May 19Jun 8Jun 25

GENELUX CorpPHARMACEUTICAL PREPARATIONSwww.genelux.com ↗

Price2.91

Change+1.93%

Gap+2.46%

Rel volume4.86×

Avg volume209.38K

Avg $ vol615.03K

SMA 202.96

SMA 502.87

SMA 2003.72

Price vs 50+1.40%

Price vs 200-21.85%

MA stackmixed

50/200 cross—

Supertrendup · 2.56

RSI (14)49

MACD hist-0.02

MACD cross—

Stoch %K / %D53 / 48

ADX (14)18

+DI / −DI17 / 18

RSI divergence—

MACD divergenceBullish

ATR %+6.08%

ADR %5.53%

52w high8.24

52w low2.30

From 52w high-64.75%

Above 52w low+26.30%

New 52w highNo

SqueezeOn · 20d

Bollinger width9.26%

%B0.31

Donchian pos47.96%

Donchian high3.16

Donchian low2.67

AVWAP (52w high)3.37

vs AVWAP high-13.83%

AVWAP (52w low)2.81

vs AVWAP low+3.28%

OBV trendFlat

Chaikin MF (20)-0.09

Today vs 20d4.86×

Avg vol (14d)223.63K

Avg vol (20d)209.38K

Avg $ vol (20d)615.03K

Market cap130.26M

RS 3m (vs SPY)+5.51%

RS 6m (vs SPY)-39.88%

RS line new highNo

Trend template2/8

Technical rank26.0

1 week+1.93%

1 month-3.49%

3 months+9.62%

6 months-33.52%

1 year+4.50%

YTD-36.15%

P/E-4.05

P/B5.68

P/S—

P/FCF-4.94

EPS-0.8600

Div yield—

ROE-140.24%

ROA-99.30%

Debt/Eq0.04

Current3.68

EV/EBITDA—

Gross margin—

Net margin—

Rev growth0.00%

EPS growth-7.62%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value121.89M

Revenue8K

Net income-8.93M

Gross profit—

Free cash flow-26.37M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out44.84M

Employees26

ListedThu, Jan 26, 2023

Free float38.23M

Float %85.3%

Short interest3.14M

Days to cover23.9d

Short volume63.7%

Squeeze score72 / 100

Next earningsThu, Aug 6, 2026 (42d)

EPS forecast−$0.20 · 2 est

Last EPS vs est—

Last surprise—

Setup gradeC

Conviction59 / 100

Pattern quality—

Tech rank26.0 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance3.21

Support2.69

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in GNLX

All disclosures →

No recent disclosed trades by Congress in GNLX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in GNLX · 10 buys

Insider	Side	Shares	Value	Traded	Filed
Smither John W Director · Common Stock · 2026-06-16	Grant	28.41K	—	2026-06-16	2026-06-18
Smither John W Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.57K	—	2026-06-16	2026-06-18
Yu Yong Chief Scientific Officer · Common Stock · 2026-06-16	Grant	119.32K	—	2026-06-16	2026-06-18
Cappello Joseph Chief Technical Officer · Common Stock · 2026-06-16	Grant	174.84K	—	2026-06-16	2026-06-18
Mirabelli Mary Director · Common Stock · 2026-06-16	Grant	28.41K	—	2026-06-16	2026-06-18
Mirabelli Mary Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.57K	—	2026-06-16	2026-06-18
Thomas John Director · Common Stock · 2026-06-16	Grant	28.41K	—	2026-06-16	2026-06-18
Tyree James L Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.57K	—	2026-06-16	2026-06-18
Thomas John Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.57K	—	2026-06-16	2026-06-18
Zindrick Thomas President and CEO · Common Stock · 2026-06-16	Grant	730.6K	—	2026-06-16	2026-06-18

SEC filings

EDGAR filings in GNLX · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.